Quarterly Report · 10-Q

AtaiBeckley Inc.

Quarterly Report

Filed Aug 11, 2026Accepted Aug 11, 2026, 4:20 PM EDTCIK 2081043Accession 0001193125-26-344720

Company context

AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has initiated Phase 3 activities; VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

Historical securities (1)

ATAINASDAQ · EQUITY · Historical · closed Sep 11, 2026

Recent company filings

Registered securities in this filing

AtaiBeckley Inc. · 10-Q · Filed 2026-08-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.01 per share

Symbol: ATAI
Exchange: NASDAQ
Classification: COMMON
Status: Historical · closed Sep 11, 2026

Filing context

Context: C_afdd05e1-7d67-492e-90f3-a7177709bfdf

Dimensions: Not supplied

Accession 000119312526344720 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.